The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: A randomized trial

Haematologica

Volumn 99, Issue 3, 2014, Pages 579-587

  van Eijk, Lucas T ^a   Heemskerk, Suzanne ^a   van der Pluijm, Rob W ^a   van Wijk, Susanne M ^a   Peters, Wilbert H M ^a   van der Hoeven, Johannes G ^a   Kox, Matthijs ^a   Swinkels, Dorine W ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; GLUTATHIONE TRANSFERASE A1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; IRON; IRON SACCHARATE; MALONALDEHYDE; PLACEBO; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; CYTOKINE; IRON CHELATING AGENT;

ADULT; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; BODY TEMPERATURE DISORDER; CHEMICAL PHENOMENA; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; IRON CHELATION; IRON LOADING; KIDNEY INJURY; LIPID PEROXIDATION; MALE; ORGAN INJURY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ACUTE KIDNEY INJURY; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HEMODYNAMICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADULT; CYTOKINES; ENDOTOXEMIA; HEMODYNAMICS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; IRON; IRON CHELATING AGENTS; MALE; OXIDATIVE STRESS; YOUNG ADULT;

EID: 84895770373     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.088047     Document Type: Article

References (43)

1. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009;1790(7):682-93.
2. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004;65(6):2108-12.
3. Li L, Frei B. Iron chelation inhibits NFkappaB-mediated adhesion molecule expression by inhibiting p22(phox) protein expression and NADPH oxidase activity. Arterioscler Thromb VascBiol. 2006;26(12): 2638-43.
4. Messaris E, Antonakis PT, Memos N, Chatzigianni E, Leandros E, Konstadoulakis MM. Deferoxamine administration in septic animals: improved survival and altered apoptotic gene expression. Int Immunopharmacol. 2004;4(3):455-9.
5. Ritter C, Andrades ME, Reinke A, Menna-Barreto S, Moreira JC, Dal-Pizzol F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med. 2004;32(2):342-9.
6. Vulcano M, Meiss RP, Isturiz MA. Deferoxamine reduces tissue injury and lethality in LPS-treated mice. Int J Immunopharmacol. 2000;22(8):635-44.
7. Kohchi C, Inagawa H, Nishizawa T, Soma G. ROS and innate immunity. Anticancer Res. 2009;29(3):817-21.
8. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. EurJClinInvest. 2002;32 (Suppl 1):9-16.
9. Zheng H, Huang X, Zhang Q, Katz SD. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int. 2006;69(4):679-84.
10. Taylor DE, Piantadosi CA. Oxidative metabolism in sepsis and sepsis syndrome. J Crit Care. 1995;10(3):122-35.
11. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61(4):290-302.
12. Victor VM, Rocha M, De la Fuente M. Immune cells: free radicals and antioxidants in sepsis. Int Immunopharmacol. 2004; 4(3):327-47.
13. Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag. 2009; 5:857-68.
14. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001;38(5):988-91.
15. Dorresteijn MJ, van Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P. Isoosmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin Res. 2005;11(5):287-93.
16. Ikuta K, Ito S, Tanaka H, Sasaki K, Torimoto Y, Fujiya M, et al. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. Clin Chim Acta. 2011; 412(23-24):2261-6.
17. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. InflammAllergy Drug Targets. 2012;11(1):66-78.
18. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006;1 (Suppl 1):S24-S31.
19. Kumpf VJ. Update on parenteral iron therapy. Nutr Clin Pract. 2003;18(4):318-26.
20. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6 (3):267-75.
21. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010;120(7):2395-405.
22. Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation. 2006;114(5):414-21.
23. Pleiner J, Mittermayer F, Schaller G, MacAllister RJ, Wolzt M. High doses of vita-min C reverse Escherichia coli endotoxininduced hyporeactivity to acetylcholine in the human forearm. Circulation. 2002;106 (12):1460-64.
24. Ramakers BP, Riksen NP, Stal TH, Heemskerk S, van den BP, Peters WH, et al. Dipyridamole augments the antiinflammatory response during human endotoxemia. Crit Care. 2011;15(6):R289.
25. Soybir N, Soybir G, Lice H, Dolay K, Ozseker A, Koksoy F. The effects of desferrioxamin and vitamin E as supplements to antibiotics in the treatment of peritonitis in rats. JR Coll Surg Edinb. 2002;47(5):700-4.
26. van Asbeck BS, Marcelis JH, van Kats JH, Jaarsma EY, Verhoef J. Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin. Eur J Clin Microbiol. 1983;2(5):432-8.
27. Sechaud R, Robeva A, Belleli R, Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008;48(8):919-25.
28. Mousavi S, Abdollahi M, Ahmadi A, Najafi A, Pazouki M, Hadjibabaie M, et al. The dilemma of hyperoxia following positive pressure mechanical ventilation: role of iron and the benefit of iron chelation with deferasirox. Eur Rev Med Pharmacol Sci. 2011;15(10):1141-8.
29. Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med. 2012; 53(4):643-8.
30. Belini Junior E, da Silva DG, Torres LS, de Almeida EA, Cancado RD, Chiattone C, et al. Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time. Ann Hematol. 2012;91 (4):479-89.
31. Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, et al. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23(6):1105-14.
32. Sechaud R, Dumortier T, Balez S. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther. 2009;47(5):321-7.
33. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica. 2008; 93(6):817-25.
34. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta. 1999;1411(2-3):437-55.
35. Grigorakaki C, Morceau F, Chateauvieux S, Dicato M, Diederich M. Tumor necrosis factor alpha-mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression. Biochem Pharmacol. 2011;82(2):156-66.
36. Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, Beka'ssy AN, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood. 2003;102(6):2053-9.
37. Buck I, Morceau F, Cristofanon S, Reuter S, Dicato M, Diederich M. The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. Int J Oncol. 2009;34(3):853-60.
38. Vreugdenhil G, Lowenberg B, van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest. 1992;22(7): 488-93.
39. Vreugdenhil G, Lowenberg B, van Eijk HG, Swaak AJ. Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int. 1990;10(3):127-30.
40. Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012;120(2):431-9.
41. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224(3):626-35.
42. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101.
43. Casanovas G, Vujic SM, Casu C, Rivella S, Strelau J, Unsicker K, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica. 2013;98 (3):444-7.